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TO THE EDITOR
Currently, standard treatment for port
wine stain (PWS) birthmarks in the
United States involves the use of lasers
or intense pulsed light to photocoagu-
late selectively the abnormal vascula-
ture. With photothermal therapy, PWS
often become lighter, but patients must
undergo many treatments (15–20 are
not uncommon; Koster et al., 2001).
Furthermore, treatment of skin types
IV–VI is difficult owing to absorption of
light by overlying epidermal melanin,
limiting treatment safety and efficacy.
Photodynamic therapy (PDT), an alter-
native treatment option, involves optical
excitation of an exogenous photosensiti-
zer and subsequent energy transfer from
the photosensitizer to oxygen to create
cytotoxic singlet oxygen (Gorman et al.,
2006). Excitation of photosensitizers
localized primarily within the intravas-
cular compartment enables targeted
vascular destruction. Treatment can be
effective but it is associated with pro-
longed photosensitivity and substantial
scarring risk (Lu et al., 2010).
Talaporfin sodium (TS) is a photosen-
sitizer with proven selective vascular
effects in preclinical studies, an accep-
table photosensitivity period of 5–7
days, and good safety data (Kujundzic
et al., 2007; Bromley et al., 2011;
Akimoto et al., 2012). Previously, we
determined that the characteristic
radiant exposure required for persistent
vascular shutdown (RE50/7 value) for
TS-mediated PDT, using a custom-built
light-emitting diode array (664 nm, full
width at half maximum¼ 20 nm), was
85 J cm 2 (Moy et al., 2012). On the
basis of these and other published data
(Smith et al., 2006; Channual et al.,
2008; Tournas et al., 2009), we hypo-
thesized that dual phototherapy
treatment with TS-mediated PDT and
ensuing pulsed dye laser (PDL) therapy
will achieve persistent vascular shut-
down with otherwise subtherapeutic
radiant exposures of PDT and PDL. To
test this hypothesis, we conducted
studies to determine the RE50/7 to
achieve persistent vascular shutdown
with PDL irradiation and the associated
RE50/7 values for dual phototherapy. We
postulate that lower radiant exposures
can be used for both TS-mediated PDT
and ensuing PDL, minimizing adverse
effects, allowing treatment of all skin
types, and potentially achieving
enhanced treatment efficacy, compared
with either alone.
Using a protocol approved by UC
Irvine Institutional Animal Care and Use
Committee, we installed dorsal window
chambers (Moy et al., 2011) on adult
C3H mice (25–30 g, n¼ 38) anesthe-
tized with isoflurane. For PDT, we used
a custom-built light-emitting diode
array centered at 664-nm excitation
(full width at half maximum¼20nm).
For TS-mediated PDT, we reconstituted
TS (Light Sciences Oncology; Bellevue,
Washington) using sterile saline to form
a solution of 25mgml1. We injected
TS (5mgkg 1) into the bloodstream
via retro-orbital injection and began
PDT immediately afterward (irradi-
ance 100 mW cm2; radiant exposure
0–260 J cm2). For PDL irradiation, we
used a clinical 595-nm laser (Vbeam
Perfecta, Candela Corporation, Wayland,
Massachusetts; 10-mm diameter spot
size, 1.5-ms pulse duration, radiant expo-
sure 3.25–10.00 J cm2). We rando-
mized the experiment order.
To test the hypothesis that the dual
therapy protocol enables persistent
vascular shutdown with lower radiant
exposures of either PDT or PDL irradia-
tion, we restricted our study to radiant
exposure values of PDT (20–60 J cm2)
and PDL (4–6 J cm 2) that were below
the associated RE50/7 values for either
treatment alone. We performed PDL
irradiation within 5 s after PDT.
To monitor blood-flow dynamics, we
used laser speckle imaging (Moy et al.,
2011). We used an experimental design
based on dose–response analysis (Moy
et al., 2012). We performed 19 experi-
ments to establish a dose–response
curve for PDL and 19 experiments for
PDTþPDL. We collected raw speckle
images before and at time points during
the ensuing week (Choi et al., 2008).
Five of the authors (BC, WJM, KMK,
BSL, and JJM) independently reviewed
the SFI images collected on day 7 and
graded them as ‘‘0’’ (no persistent
vascular shutdown) or ‘‘1’’ (persistent
vascular shutdown achieved). Prism
(version 5.0d, GraphPad Software, San
Diego, California) was used to estimate
the RE50/7 for each study. We used an F-
test to compare the log (RE50/7) values
determined from PDT (85 J cm2 from
Moy et al. (2012)) and PDTþPDL. Our
null hypothesis was that the RE50/7
values for the two studies do not differ
in a statistically significant manner.
We observed three dose-dependent
responses: (1) minimal acute change in
blood flow and no persistent vascular
shutdown (Figure 1a); (2) marked acute
change in blood flow, followed by
partial-to-full recovery of blood flow
and no persistent vascular shutdown
(Figure 1b); and (3) marked acute or
delayed reduction in blood flow, fol-
lowed by complete vascular shutdown
at day 7 (Figure 1c). With application of
dose–response methodology, we esti-
mated an RE50/7 of 7.1 J cm
2 requiredAccepted article preview online 18 July 2014; published online 14 August 2014
Abbreviations: LSI, laser speckle imaging; PDL, pulsed dye laser; PDT, photodynamic therapy; PWS, port
wine stain; SFI, speckle flow index; TS, talaporfin sodium
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to induce persistent vascular shutdown
with PDL irradiation (Figure 1d). With
PDTþPDL, the characteristic PDT radi-
ant exposure required to achieve
persistent vascular shutdown, decreased
from 85 to 45 J cm2 (Figure 1e).
This difference in PDT RE50/7 was
found to be statistically significant
(P¼ 0.0002).
We evaluated the degree of synergy
between PDT and PDL vascular effects
with dual phototherapy (Madsen et al.,
2002):
a ¼ fPDT fPDL
fPDT þPDL
ð1Þ
where fraction of photodynamic therapy
experiments (fPDT) and fraction of pulsed
dye laser experiments (fPDL) are the
fractions of single-phototherapy experi-
ments and fPDTþPDL is the fraction of
combined experiments, which do not
induce persistent vascular shutdown.
An additive (or absence of any) effect
is indicated by degree of interaction
(a)¼1, a41 indicates a synergistic
effect, and ao1 indicates an antagonistic
effect. Our data (Table 1) suggest the
synergistic nature (a¼2.7) of PDTþPDL.
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Figure 1. The combination of talaporfin sodium (TS)-mediated photodynamic therapy (PDT) and pulsed dye laser (PDL) irradiation leads to a significant reduction in
the characteristic PDT radiant exposure required to achieve persistent vascular shutdown. We first determined the characteristic radiant exposures associated with
persistent vascular shutdown following 595-nm PDL irradiation. We performed PDL on the epidermal side of window chambers and imaged blood flow using laser
speckle imaging (LSI). We assessed persistent vascular shutdown on day 7. We assigned a ‘‘0’’ score if some evidence of blood flow was present, and a ‘‘1’’ score if flow
was no longer evident. We used dose–response analysis to calculate a characteristic radiant exposure (RE50/7) at which 50% of irradiated window chambers are
expected to have vascular shutdown on day 7. (a–c) Representative LSI data associated with 595-nm PDL irradiation, in which persistent vascular shutdown was not (a,
b) and was (c) achieved, using radiant exposures of (a) 4, (b) 6, and (c) 10 J cm2, respectively. (d) On the basis of data from 19 experiments, we identified an RE50/7 of
7.1 J cm 2 for PDL irradiation. We then studied the combination of TS-mediated PDT and PDL irradiation. In this set of experiments, we used PDT (20–60 J cm2) and
PDL radiant exposures (4–6 J cm 2) that were below the RE50/7 values of 85 J cm
 2 (Moy et al., 2012) and 7.1 J cm2 (d), respectively. (e) Representative maps of blood
flow that demonstrate persistent vascular shutdown at day 7. In this specific example, we applied PDT (60 J cm2) followed by PDL (6 J cm 2). This combination
resulted in marked acute vascular shutdown, which persisted through day 7. (f) On the basis of data from 30 experiments, we determined that the characteristic radiant
exposure required to achieve persistent vascular shutdown decreased from 85 J cm2 with PDT alone to 45 J cm 2 for the combined PDTþ PDL protocol. Bar¼ 2 mm.
Table 1. Summary of observations of persistent vascular shutdown for
experiments in which the PDT radiant exposure was 20–60 J cm 2 and/or
the PDL radiant exposure was 4–6 J cm2
Experimental
condition
Number of experiments
meeting criterion
Number of occurrences of
persistent vascular shutdown
fPDT, fPDL, or
fPDTþPDL
PDT 4 0 100%
PDL 7 1 86%
PDTþ PDL 19 13 32%
Abbreviations: fPDL, fraction of pulsed dye laser experiments; fPDT, fraction of photodynamic therapy
experiments; fPDTþPDL, fraction of combined experiments; PDL, pulsed dye laser;
PDT, photodynamic therapy.
The PDT data are taken from Moy et al. (2012). On the basis of these data and equation 1, the degree of
interaction is 2.7, suggesting that PDT and PDL irradiation together achieve a synergistic shutdown effect.
KM Kelly et al.
Combined Photodynamic/Photothermal Therapy
www.jidonline.org 303
Collectively, our results reveal that PDTþ
PDL reduces the PDT light dose required
to achieve persistent vascular shutdown,
even at low PDL radiant exposures. We
hypothesize that TS-mediated PDT
enhances persistent vascular shutdown
achieved with ensuing PDL therapy, pri-
marily via endothelial cell damage (Mitra
and Foster, 2008); mechanistic studies
currently are underway.
Dual phototherapy represents a poten-
tial new approach for more effective
treatment of PWS birthmarks. We have
initiated a trial approved by the Investiga-
tional Review Board to evaluate intrave-
nously administered TS/664-nm laser
light–mediated dual phototherapy for
PWS treatment. Treatment has been pain-
less and notable lesion lightening has
been achieved with both PDT and
PDTþPDL in a single session. Patients
are photosensitive for 5–7 days post
procedure, and for the first 72hours they
must remain indoors with lights dimmed.
Completion of this study will determine
whether lesion lightening is greater with
dual phototherapy than PDL alone. It is
our intent that this combined low-energy
dual phototherapy will offer clinicians
and patients of all skin types improved
lesion lightening in fewer treatments.
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TO THE EDITOR
Familial keratoacanthomas (KAs) are
characterized by the appearance of
multiple epithelial tumors that are beli-
eved to arise from adjoining hair folli-
cles (Schwartz, 1994). These lesions,
which phenotypically and histologi-
cally resemble squamous cell carcino-
mas (SCCs) (Cribier et al., 1999), have
a fast evolution and spontaneous
regression. To date, four familial forms
of multiple KAs have been described:
(1) multiple self-healing squamousAccepted article preview online 22 July 2014; published online 11 September 2014
Abbreviations: KA, keratoacanthoma; MSPC, multiple self-healing palmoplantar carcinoma; MSSE,
multiple self-healing squamous epithelioma; SCC, squamous cell carcinoma
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